Allergic rhinitis (AR), chronic rhinosinusitis (CRS) and asthma often co-exist. The one airway model proposes that disease mechanisms occurring in the upper airway may mirror lower airway events. Airway remodelling is the term used to describe tissue structural changes that occur in a disease setting and reflect the dynamic process of tissue restructuring during wound repair. Remodelling has been long identified in the lower airways in asthma and is characterized by epithelial shedding, goblet cell hyperplasia, basement membrane thickening, subepithelial fibrosis, airway smooth muscle hyperplasia and increased angiogenesis. The concept of upper airway remodelling has only recently been introduced, and data so far are limited and often conflicting, an indication that more detailed studies are needed. Whilst remodelling changes in AR are limited, CRS phenotypes demonstrate epithelial hyperplasia, increased matrix deposition and degradation along with accumulation of plasma proteins. Despite extensive research over the past years, the precise cellular and molecular mechanisms involved in airway remodelling remain incompletely defined. This review describes our current rather limited understanding of airway remodelling processes in AR, CRS and asthma and presents mechanisms both shared and distinct between the upper and lower airways. Delineation of shared and disease-specific pathogenic mechanisms of remodelling between the sinonasal system and the lung may guide the rational design of more effective therapeutic strategies targeting upper and lower airways concomitantly and improving the health of individuals with inflammatory airway diseases.
| INTRODUCTION
Tissue modelling can occur in any organ in relation to inflammation or mechanical injury with the aim of restoration to normal tissue architecture. Abnormal restitution or reconstruction of the damaged tissue is termed remodelling. Airway remodelling is well recognized as a hallmark feature of the asthmatic lung that is often associated with more severe phenotypes of the disease; 1 still, its relevance in upper airway disease remains poorly defined. Moreover, the exact pathogenetic mechanisms that lead to airway remodelling are still mostly unexplored.
It is clearly established that the upper and lower airways share common disease associations and immunopathological mechanisms. 2 The demonstration that nasal provocation with allergen can induce bronchial inflammation along with the observation that the converse is also true confirmed the bidirectional nature of the one airway system. 3, 4 As a result, the term 'one airway' or 'united airways' have been established. [5] [6] [7] In fact, up to 40% of allergic rhinitis (AR) patients report asthma symptoms and up to 80% of asthmatics have symptomatic AR. 8 Chronic rhinosinusitis (CRS) and asthma severity also co-associate. 9 Sinus disease is evident in up to 88% of mildmoderate asthmatics and in up to 100% in severe steroid-dependent asthma on sinonasal imaging. 
| AIRWAY STRUCTURE IN HEALTH
The respiratory mucosa is made up of pseudostratified ciliated columnar epithelium and the supporting lamina propria. The airway epithelium acts as a physical barrier to the external environment, is continuously exposed to pollutants, allergens and microbes and responds directly by modulating innate and adaptive immune responses. 12 The lower airway mucosa is identical to that of the upper airway apart from the presence of airway smooth muscle (ASM) that extends from the trachea to the terminal bronchiole. The vascular network remains substantial. Ciliated cuboidal epithelium often lines the terminal bronchioles.
The epithelium sits on the basement membrane (BM), which is composed of an upper layer called the basal lamina (true basement membrane) mainly consisting of type IV collagen and type V laminin. 13 The epithelium is attached to the lamina densa. Extending internally from the lamina densa is the lamina reticularis or reticular basement membrane (RBM) derived from the attenuated fibroblast sheath located below. 13 The BM compartmentalizes the epithelium from the underlying mesenchymal components and allows epithelial and inflammatory cell migration. 14 The lamina propria below the BM contains mucus/serous glands that support mucus secretion and airway hydration. It is composed of polysaccharides, collagens and water that confer tensile strength accompanied by elasticity and compressibility. It is these extracellular matrix (ECM) relative proportions of these components that contribute to the physical properties of the airway. The ECM has a pivotal role in regulating cellular function, acting as a substrate for cellular adhesion, migration, differentiation, proliferation and survival and as a scaffold. 15 Airway fibroblasts are localized beneath the BM and, when activated, become myofibroblasts, characterized by the expression of alpha smooth muscle actin (a-SMA), with rapid ECM production. 16 ECM turnover is orchestrated by the balance between the expression of matrix metalloproteinases (MMP) and their inhibitors (TIMP). 17 
| RESTORATION OF N ORMAL AIRWAY STRUCTURE (MOD ELLING)
The airway mucosa must be resilient to environmental insults and rapidly induce tissue repair after damage. Airway injury leads to inflammation and is associated with the release of cytotoxic mediators, free oxygen radicals and collagenases by inflammatory and structural cells. If the airway surface is vulnerable, either intrinsically or as a result of disease, epithelial and BM integrity becomes compromised. 18 As a result, epithelial cells express adhesion molecules, cytokines and growth factors to induce tissue repair and restoration. 19 The repair process begins with the deposition of ECM proteins over the denuded epithelium. 20 The ECM matrix acts as a substrate over which the basal epithelial cells at the 'wound edge' can attach to, proliferate, flatten out and migrate over and is composed of the remnant components of the BM, such as, type IV collagen and laminin, and blood-derived factors including fibrin and fibronectin. Activation of the attenuated fibroblast sheath is evident, particularly in response to signals from the transforming growth fac- 29 This may be related to the ability of IL-13 to induce the production of TGF-b1, although IL-13 can also induce airway fibrosis in TGF-b1-independent pathways. 30 Other cytokines with increased expression in the airways of asthmatics, such as osteopontin, are also closely associated with airway inflammation and remodelling. [31] [32] [33] Osteopontin is increased in the asthmatic airway and in vitro studies reveal a potent effect on fibroblast and ASM proliferation, whilst osteopontin -/-mice demonstrate less airway remodelling following allergen challenge. and VEGFR1-dependent pathways. 40 Apart from the cytokine milieu, it is important to consider other mechanisms by which inflammation may promote or modulate remodelling. Eosinophils are a rich source of mediators that can directly injure tissue and induce remodelling. 41 Eosinophil depletion attenuates airway remodelling, supporting also the view that eosinophil-derived TGF-b1 is a key player. 42 In addition, eosinophildepleted mice are protected from peribronchial collagen deposition and ASM mass in response to chronic allergen exposure. 43 IL-5-deficient mice display markedly less total lung collagen, peribronchial collagen type III and IV deposition, and a-SMA expression following chronic allergen challenge. 44 Interestingly, studies in humans using a monoclonal antibody against IL-5 demonstrated a reduction in airway eosinophils associated with decreased TGF-b1 in bronchoalveolar lavage (BAL) and lower expression of the ECM components, tenascin, lumican and procollagen III. 45 However, the linear model suggesting that environmental sensitization leads to Th2 cell-driven allergic inflammation and subsequent airway remodelling has been challenged by studies in childhood asthma. Bronchial biopsies from asthmatic children show marked remodelling very early on in the disease 46 that may even predate the onset of symptoms by up to four years, suggesting that remodelling is an early feature of allergic asthma and not necessarily a result of chronic airway inflammation. 47 Other studies confirm that airway remodelling markers, such as RBM thickening and abnormal structural cell activation, are consistently present in childhood asthma and may occur in the absence of eosinophilic inflammation. 48 Furthermore, inflammation and remodelling can be dissociated as shown by allergen provocation in adult asthma, wherein rapid and simultaneous activation of inflammation and airway remodelling occurs but dissociation of selected aspects of remodelling, such as collagen deposition and AHR, is evident at later time points. 49 In fact, whilst RBM thickening may reflect remodelling events deeper in the submucosa, 50 there is little or no correlation of RBM thickness with the duration of asthma 46 or inflammation, 51 suggesting that RBM thickening may be overall independent of inflammation. It is therefore conceivable that remodelling is initiated due to an intrinsic propensity of the lower airway of asthmatics for injury and abnormal repair and becomes later on exacerbated by aberrant inflammatory responses. 53 This is important in that fibroblast accumulation and ASM hypertrophy are the selective determinants of severe and persistent asthma symptoms. 54 Polymorphisms in ADAM33 are associated with a more rapid annual decline in postbronchodilator forced expiratory volume in one second (FEV1). 55 Such genetic associations may explain why severity and outcomes in adult asthma can to a certain extent be predicted in childhood and do not necessarily relate to inflammatory biomarkers. 56 Increased ASM numbers seem to be the cause rather than the consequence of severe disease in asthma. ASM cells produce high levels of inflammatory cytokines and growth factors, such as GM-CSF, IL-1b, IL-5, IL-6, eotaxin, bFGF, PDGF-B and VEGF in the airways. 57 Moreover, ASM cells of asthmatics release large amounts of IL-6 and IL-8 after stimulation with house dust mite (HDM) or following rhinovirus infection. 58 Interestingly, large-scale transcriptional profiling analyses of ASM cells from asthmatic versus nonasthmatic subjects revealed a marked activation of pathways linked to cell proliferation and growth, vascularization, inflammatory response genes and muscle-tissue-specific responses, such as contractility in asthmatics. 59 Finally, ASM contraction can alter the mechanical properties of the airway wall, promoting mechanotransduction pathways that contribute to remodelling and initiating cascades that synergize with other inflammatory mechanisms. 60 Enhanced vascularity correlates with asthma severity 61 and is a key feature in the airways of people who died from asthma. 62 Changes to the airway vasculature include increased numbers of vessels per unit area with enhanced vessel size and associated vasodilation and leakage leading to mucosal oedema. Increased vascularity is present even in mild asymptomatic asthma. 63 The model of airway wall remodelling proposed by Moreno et al. 64 suggests that even small increases in airway thickness significantly contribute to the airway obstruction observed after allergen challenge in asthma. MMPs and osteopontin, 31, 65, 66 all of which activate the underlying mesenchymal cell unit and, ultimately lead to RBM thickening, subepithelial fibrosis and smooth muscle hyperplasia. 67 This epithelium-fibroblast signalling pathway is termed the epithelial-mesenchymal trophic unit (EMTU) 68 and may, at least partly, explain the observed dissociation between inflammation and airway remodelling events.
In health, the epithelium is able to repair rapidly; still, in asthma, there is increasing evidence that this process is defective with prolonged epithelial cell activation and signalling to the underlying mesenchymal cells, leading to myofibroblast transformation. Evidence for defective epithelial repair exists in that markers of proliferation, such as Ki67, are reduced at an early age. 69 Increased expression of the epidermal growth factor receptor (EGFR) with subsequent pro-fibrotic growth factor release also occurs in response to injury and is a marker of active epithelial repair. 69 In normal epithelium, elevated EGFR is only observed in areas of structural damage; still, in asthma, EGFR is induced in both damaged and normal epithelium, pointing to diffuse epithelial injury. Overall, remodelling in the lower airways is a complex process in asthma and a definite unifying mechanistic pathway is uncertain.
However, the observation that remodelling and asthma severity strongly correlate suggests causality. Recently, the realization that upper airway remodelling may have a similar impact on AR and CRS has initiated more focused research to dissect the relevance of structural changes in the immunopathology of these conditions.
| ALLERGIC RHIN ITIS AND NASAL

REMODELLING
Allergic rhinitis is mainly driven by Th2 cell-associated inflammation.
Up to 80% of asthmatics have AR, and this has formed the basis of treatment guidelines reminding clinicians to treat AR in asthmatics. 71 Paired upper and lower airway bronchoscopic samples from patients with AR and allergic asthma confirm similar Th2 cell-driven inflammation in the nasal and bronchial mucosa. 72 If the linear model that inflammation leads to remodelling is followed, then persistent structural changes should be key findings in AR as is the case in asthma.
However, the evidence for remodelling changes in AR is conflicting and suggests that remodelling does not occur or is not a prominent feature in AR. Moreover, animal models of AR are limited and not helpful as disease provocation is obtained via ovalbumin exposure and thus does not relate to human disease. Hence, we will discuss current knowledge obtained predominantly through human studies.
Allergen exposure in individuals with perennial (PAR) and seasonal allergic rhinitis (SAR) leads to rapid activation and amplification of inflammatory pathways almost identical to those occurring in asthma. Both perennial (HDM related) and seasonal (pollen related) subtypes of disease increase eosinophilic mucosal inflammation postintranasal challenge. In SAR, nasal biopsies at baseline showed increased overall BM thickness compared to healthy tissue, but 24 hours after allergen challenge, despite eosinophil influx, further increase in BM thickening did not occur. 73, 74 Moreover, no change in epithelial thickness or submucosal collagen deposition was observed. In individuals with PAR and HDM sensitization, BM thickness was also comparable to the normal nasal mucosa 73 and no further increase following HDM provocation was noted. In contrast, an early study reported loss of epithelial integrity in relation to the degree of eosinophilia in PAR. 75 Collectively, considering that the nasal mucosa is highly adapted to meet environmental insults, one can speculate that it is more adept in responding to inflammation and can induce tissue restoration more effectively compared to the lower airway. In this context, patients defective in nasal tissue repair may have a yet unidentified, predisposing factor that renders them more susceptible to CRS and/ or asthma. 78 
| CH RONIC R HIN OSIN USITIS AND SINON ASAL REMODELLING
Chronic rhinosinusitis is a broad term that incorporates a group of heterogeneous inflammatory disorders 79 and is subdivided into disease with and without nasal polyps (CRSwNP and CRSsNP, respectively), with even more inflammatory and remodelling subtypes. 80 CRS is very different to AR both in mucosal location of disease and the pattern of severity of inflammation. Thus, remodelling in CRS is expected to be different from any in AR and maybe more relevant to studying remodelling in asthma. CRS and asthma are strongly associated and up to 14% CRSwNP and aspirin-exacerbated respiratory disease patients demonstrate severe asthma. 81 Such a strong relationship between two disease groups is intriguing and suggests common genetic predisposition and mechanistic pathways exist. 82 Unlike AR, tissue remodelling is a hallmark in CRS. CRSwNP is now emerging as CRS subgroup with different endotypes. 82 CRSwNP still represents a more defined immunological entity with a more Th2-driven inflammatory pathway. In contrast, CRSsNP has more diverse immunological endotypes that remain poorly defined. 83 In CRSwNP, eosinophilic inflammation is present with amplification of IL-4-, IL-5-and IL-13-driven pathways. Recent work has highlighted type II ILC-infiltrated polyp tissue with Th2-skewed cells expressing IL-25R and IL-33R. 84, 85 Inflammatory response amplification via bacterial super-antigens is also observed and leads to enhanced nasal IgE production. 86 In contrast, CRSsNP is characterized by a distinct inflammatory pattern, with a Th1 cell bias and excess interferon-c (IFN-c) and neutrophilic inflammation. 87 Whilst both CRS phenotypes have a high incidence of lower airway disease with asthma and bronchiectasis, the poor ability to subtype CRSsNP inflammatory profiles makes it difficult to compare remodelling changes with those occurring in the lower airway. Thus, we will compare remodelling in CRSwNP to asthma aiming to decipher upper and lower airway link in shared disease mechanisms.
In CRSwNP, epithelial cell disruption is extensive in whole nasal tissue samples 88 and excess mucus can be explained by goblet cell hyperplasia and mucin hypersecretion. 89 BM thickening relates to disease severity and duration, along with the presence of underlying asthma 90 and seems to be independent of the degree of eosinophilic inflammation. 91 Immunohistochemical studies demonstrate that the sinonasal epithelium can transition to a mesenchymal phenotype, in both CRSwNP and CRSsNP, and markers, such as E-cadherin, cytokeratin and vimentin expression, correlate with fibrosis parameters, including BM thickening. | 997
The finding of lower TGF-b1/2 levels along with diminished signalling pathway components in CRSwNP, compared to CRSsNP, suggests the latter is a more fibrotic subtype of rhinosinusitis. 94 The lack of TGF-b1 could also explain the propensity to excess Th2 cell inflammation and the scarcity of regulatory T cells (Tregs) in polyp tissue and nasal mucosa. 95 Still, given that eosinophils produce TGF- F I G U R E 1 Representative microphotographs of A, bronchial tissue from a healthy control individual and a patient with severe asthma depicting increased airway angiogenesis (CD34+ staining), reticular basement membrane thickening (H&E stain) and goblet cell hyperplasia (PAS stain). B, Nasal mucosal tissue from a healthy control and a patient with AR with similar appearances on basic staining, and CRSwNP depicting typical remodelling changes with denuded epithelium and extensive pseudocyst formation. Nasal images courtesy of Miss Nara Orban, Imperial College London collagen and other ECM production in CRSwNP. These contradictory findings may be due to the failure to report on location-specific expression and quantification of growth factors. Alternatively, and/or in conjunction, one should consider the structure of a nasal polyp. In Table 1 , we summarize the gross histopathological changes seen in a remodelled airway in AR, CRS, and asthma. Regarding AR, F I G U R E 2 Potential key pathways and factors involved in airway remodelling processes in the upper and lower airways SAMITAS ET AL.
no remodelling changes whatsoever are observed in the epithelium and submucosa, other than possibly some basement membrane thickening. In CRSwNP and allergic asthma, however, several changes do occur that have important similarities. In both, disruption and shedding of epithelial cells are excessive along with goblet cell hyperplasia.
EMTU activation is extensive in both and maybe predisposed to because of epithelial vulnerability leading to active submucosal mesenchymal activation. Regarding the submucosa, similar remodelling processes in CRSwNP and allergic asthma include the hypertrophy of mucus glands and the excess production of ECM components; however, significant differences also exist; pseudocysts exist only in CRSwNP whilst increased angiogenesis is observed only in allergic asthma. There is emerging overlap with common inflammatory and growth factor pathways in asthma and CRS pheno-endotypes, but more work is still needed to understand any overlap pathways. Basic similarities and differences in remodelling events observed in AR, CRSwNP and allergic asthma are depicted in Figure 1 .
| CONCLUSIONS
Airway remodelling is an active and highly complex process. The 
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